StaffNovember 28, 2018
Partnership Will Investigate Advanced Parenteral Cannabinoid-Based Formulations For Acute Treatment of Convulsive Disorders. DENVER, CO -November 28, 2018 /AxisWire/ Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as […]
